Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
作者信息
Di Loreto Chiara, Minarelli Viviana, Nasini Giovanni, Norgiolini Roberto, Del Sindaco Paola
机构信息
Diabetes Clinic, USL Umbria 1, Perugia Territorial Health Structure, Perugia, Italy.
Diabetes Clinic, USL Umbria 1, Città di Castello Hospital, Città di Castello, Italy.
出版信息
Diabetes Ther. 2022 Jun;13(6):1251. doi: 10.1007/s13300-022-01263-7.
Abstract
摘要
相似文献
1
Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
Diabetes Ther. 2022 Jun;13(6):1251. doi: 10.1007/s13300-022-01263-7.
2
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.司美格鲁肽每周一次用于2型糖尿病患者的真实世界有效性：初治或从其他胰高血糖素样肽受体激动剂转换而来的患者：一项在翁布里亚进行的回顾性观察研究结果
Diabetes Ther. 2022 Mar;13(3):551-567. doi: 10.1007/s13300-022-01218-y. Epub 2022 Mar 1.
3
Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?司美格鲁肽用于2型糖尿病——它是最佳的胰高血糖素样肽1受体激动剂（GLP-1R激动剂）吗？
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):371-377. doi: 10.1080/17425255.2018.1441286. Epub 2018 Feb 23.
4
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.每周一次司美格鲁肽与其他 GLP-1 受体激动剂在 2 型糖尿病中的成本效益比较：系统文献回顾。
Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):221-233. doi: 10.1080/14737167.2021.1860022. Epub 2021 Jan 12.
5
Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).美国临床实践中（STAY研究），起始使用每周一次与每日一次注射用胰高血糖素样肽-1受体激动剂的2型糖尿病患者的持续治疗率和依从率更高。
Diabetes Ther. 2022 Jan;13(1):175-187. doi: 10.1007/s13300-021-01189-6. Epub 2021 Dec 16.
6
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.在斯洛伐克，每周一次司美格鲁肽与每周一次度拉鲁肽治疗 2 型糖尿病的管理：一项长期成本效益分析。
Adv Ther. 2019 Aug;36(8):2034-2051. doi: 10.1007/s12325-019-00965-y. Epub 2019 Jun 5.
7
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.每周一次司美格鲁肽治疗 2 型糖尿病患者：荷兰的成本效益分析。
BMJ Open Diabetes Res Care. 2019 Oct 1;7(1):e000705. doi: 10.1136/bmjdrc-2019-000705. eCollection 2019.
8
Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.接受胰高血糖素样肽-1受体激动剂治疗的2型糖尿病患者的心脏-肾脏比较结局：一项网状荟萃分析
Front Pharmacol. 2021 Dec 24;12:759262. doi: 10.3389/fphar.2021.759262. eCollection 2021.
9
[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].[司美格鲁肽，每周一次的胰高血糖素样肽-1受体激动剂（奥泽米皮克®）]
Rev Med Liege. 2019 Sep;74(9):488-494.
10
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.每周一次司美格鲁肽与每日一次利拉鲁肽治疗2型糖尿病的疗效比较：爱沙尼亚的长期成本效益分析
Diabetes Ther. 2019 Feb;10(1):159-176. doi: 10.1007/s13300-018-0542-x. Epub 2018 Dec 7.
引用本文的文献
1
Semaglutide in routine clinical practice: interesting news from real-world evidence.司美格鲁肽在常规临床实践中的应用：来自真实世界证据的有趣消息。
J Endocrinol Invest. 2022 Aug;45(8):1599-1600. doi: 10.1007/s40618-022-01810-w. Epub 2022 May 6.
Zotero 插件